Burgess Statement on House Passage of the FDA Reauthorization Act of 2017

f t # e
Washington, July 12, 2017 | comments

Washington, D.C. — Congressman Michael C. Burgess, M.D. (R-TX), Chairman of the Energy and Commerce Subcommittee on Health, released the following statement on the House’s passage of H.R. 2430, the FDA Reauthorization Act of 2017 (FDARA), which reauthorizes FDA’s critical user fee programs.

“The passage of FDARA ensures that American patients will have access to innovative cures and treatments, and that the United States will maintain its position as a global leader in medical innovation. This legislation is a big win for patients and the millions of Americans who work in the health care sector. Enactment of FDARA will ensure that groundbreaking treatments, drugs, and devices will reach patients sooner, undoubtedly saving lives and improving care.” 
f t # e